I must commend you for your excellent command of s
Post# of 72446
(Total Views: 226)
Posted On: 06/29/2017 11:15:47 AM
Re: starboardtack #35377
I must commend you for your excellent command of soft-bashing techniques, based on false assumptions.
I believe that most here can see through this kind of post.
Nevertheless, I point out a few things, like your trying to trivialize IPIX's current trials by dismissing them as "cheap small proof-of-concept trials." Mr. Ehrlich has done a spectacular job of getting clinical trials going on very little money. Given that the FDA is being heavily criticized for the way that it does business, and is trying to speed up the approval process, there is no basis for claiming that IPIX's trial will require a do-over at the kind of high prices you list. Please tell us how you arrive at a 30 million dollar price tag for these trials (which would be extremely surprising). Indeed the Bril-ABSSSI trial is on hold because of the estimated cost of 30 million -- but the other trials are proceeding because they are much cheaper, as the company has stated on numerous occasions. Your claim that 2 trials would each cost 30 million is false.
Your claim that there will be 30% dilution is also false. If a partnership is achieved, no dilution will be necessary. If some financing via Aspire is necessary, they certainly are not going to do your (bogus) estimate of 46 million all at the same time, and at this low share price. This claim of huge dilution is a fantasy, based on what appears to be your desire to scare potential new shareholders away.
You've got the third strike confirmed now.
I believe that most here can see through this kind of post.
Nevertheless, I point out a few things, like your trying to trivialize IPIX's current trials by dismissing them as "cheap small proof-of-concept trials." Mr. Ehrlich has done a spectacular job of getting clinical trials going on very little money. Given that the FDA is being heavily criticized for the way that it does business, and is trying to speed up the approval process, there is no basis for claiming that IPIX's trial will require a do-over at the kind of high prices you list. Please tell us how you arrive at a 30 million dollar price tag for these trials (which would be extremely surprising). Indeed the Bril-ABSSSI trial is on hold because of the estimated cost of 30 million -- but the other trials are proceeding because they are much cheaper, as the company has stated on numerous occasions. Your claim that 2 trials would each cost 30 million is false.
Your claim that there will be 30% dilution is also false. If a partnership is achieved, no dilution will be necessary. If some financing via Aspire is necessary, they certainly are not going to do your (bogus) estimate of 46 million all at the same time, and at this low share price. This claim of huge dilution is a fantasy, based on what appears to be your desire to scare potential new shareholders away.
You've got the third strike confirmed now.
(6)
(0)